Class information for:
Level 1: SIBUTRAMINE//ORLISTAT//LORCASERIN

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
7029 1414 45.2 74%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
1 4 ECONOMICS//EDUCATION & EDUCATIONAL RESEARCH//PSYCHOL 3876184
43 3       NUTRITION & DIETETICS//OBESITY//EATING DISORDERS 96942
519 2             OVERWEIGHT//OBESITY//SIBUTRAMINE 15074
7029 1                   SIBUTRAMINE//ORLISTAT//LORCASERIN 1414

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 SIBUTRAMINE authKW 3724991 19% 65% 264
2 ORLISTAT authKW 1959369 14% 48% 191
3 LORCASERIN authKW 458741 3% 59% 36
4 PHENTERMINE authKW 447906 3% 45% 46
5 ANTI OBESITY DRUGS authKW 446889 3% 42% 49
6 ANTI OBESITY AGENTS authKW 324206 2% 48% 31
7 OBES CLIN TRIALS PROGRAM address 172747 1% 100% 8
8 CONTRAVE authKW 153551 1% 89% 8
9 DEXFENFLURAMINE authKW 152644 2% 21% 33
10 LIPASE INHIBITOR authKW 125703 1% 31% 19

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 Endocrinology & Metabolism 9562 32% 0% 453
2 Nutrition & Dietetics 8515 21% 0% 294
3 Pharmacology & Pharmacy 2603 27% 0% 375
4 Medicine, General & Internal 1717 17% 0% 244
5 Primary Health Care 366 2% 0% 24
6 Toxicology 107 3% 0% 48
7 Cardiac & Cardiovascular System 62 4% 0% 56
8 Peripheral Vascular Diseases 51 3% 0% 36
9 Psychiatry 32 3% 0% 41
10 Health Care Sciences & Services 15 1% 0% 16

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 OBES CLIN TRIALS PROGRAM 172747 1% 100% 8
2 COMPREHENS WEIGHT CONTROL 97167 0% 75% 6
3 COMPREHENS WEIGHT CONTROL PROGRAM 55679 0% 37% 7
4 OBES CLIN TRIALS PROGRAMME 49353 0% 57% 4
5 ENDOCRINOL OBES EATING DISORDERS GRP 48584 0% 75% 3
6 METAB DISORDERS ENDOCRINOL 48584 0% 75% 3
7 HOSP ENRIQUE TORNU 43187 0% 100% 2
8 PRECLIN CLIN DRUG DEV 43187 0% 100% 2
9 G DESCOVICH ATHEROSCLEROSIS STUDY 37307 1% 16% 11
10 SOROKA UMC 32387 0% 50% 3

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 INTERNATIONAL JOURNAL OF OBESITY 39244 8% 2% 111
2 OBESITY RESEARCH 36998 4% 3% 51
3 DIABETES OBESITY & METABOLISM 11966 2% 2% 35
4 OBESITY 8960 3% 1% 41
5 OBESITY FACTS 5708 1% 2% 11
6 OBESITY REVIEWS 4602 1% 1% 15
7 CLINICAL PHARMACOLOGY & THERAPEUTICS 2277 2% 0% 25
8 OBESITY AND METABOLISM-MILAN 2019 0% 3% 3
9 EXPERT OPINION ON PHARMACOTHERAPY 1666 1% 1% 15
10 ENDOCRINE PRACTICE 1575 1% 1% 9

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 SIBUTRAMINE 3724991 19% 65% 264 Search SIBUTRAMINE Search SIBUTRAMINE
2 ORLISTAT 1959369 14% 48% 191 Search ORLISTAT Search ORLISTAT
3 LORCASERIN 458741 3% 59% 36 Search LORCASERIN Search LORCASERIN
4 PHENTERMINE 447906 3% 45% 46 Search PHENTERMINE Search PHENTERMINE
5 ANTI OBESITY DRUGS 446889 3% 42% 49 Search ANTI+OBESITY+DRUGS Search ANTI+OBESITY+DRUGS
6 ANTI OBESITY AGENTS 324206 2% 48% 31 Search ANTI+OBESITY+AGENTS Search ANTI+OBESITY+AGENTS
7 CONTRAVE 153551 1% 89% 8 Search CONTRAVE Search CONTRAVE
8 DEXFENFLURAMINE 152644 2% 21% 33 Search DEXFENFLURAMINE Search DEXFENFLURAMINE
9 LIPASE INHIBITOR 125703 1% 31% 19 Search LIPASE+INHIBITOR Search LIPASE+INHIBITOR
10 PHENTERMINE TOPIRAMATE 117561 0% 78% 7 Search PHENTERMINE+TOPIRAMATE Search PHENTERMINE+TOPIRAMATE

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref.
in cl.		 Shr. of ref. in
cl.		 Citations
1 YANOVSKI, SZ , YANOVSKI, JA , (2014) LONG-TERM DRUG TREATMENT FOR OBESITY A SYSTEMATIC AND CLINICAL REVIEW.JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. VOL. 311. ISSUE 1. P. 74-86 52 74% 147
2 SHARMA, B , HENDERSON, DC , (2008) SIBUTRAMINE: CURRENT STATUS AS AN ANTI-OBESITY DRUG AND ITS FUTURE PERSPECTIVES.EXPERT OPINION ON PHARMACOTHERAPY. VOL. 9. ISSUE 12. P. 2161-2173 96 71% 16
3 SIEBENHOFER, A , JEITLER, K , HORVATH, K , BERGHOLD, A , POSCH, N , MESCHIK, J , SEMLITSCH, T , (2016) LONG-TERM EFFECTS OF WEIGHT-REDUCING DRUGS IN PEOPLE WITH HYPERTENSION.COCHRANE DATABASE OF SYSTEMATIC REVIEWS. VOL. . ISSUE 3. P. - 74 79% 0
4 IOANNIDES-DEMOS, LL , PROIETTO, J , MCNEIL, JJ , (2005) PHARMACOTHERAPY FOR OBESITY.DRUGS. VOL. 65. ISSUE 10. P. 1391 -1418 80 74% 70
5 PLOCK, N , BAX, L , LEE, D , DEMANNO, D , LAHU, G , PFISTER, M , (2017) EXPLORATORY LITERATURE META-ANALYSIS TO CHARACTERIZE THE RELATIONSHIP BETWEEN EARLY AND LONGER TERM BODY WEIGHT LOSS FOR ANTIOBESITY COMPOUNDS.JOURNAL OF CLINICAL PHARMACOLOGY. VOL. 57. ISSUE 1. P. 52 -63 67 66% 0
6 HALFORD, JCG , (2004) CLINICAL PHARMACOTHERAPY FOR OBESITY: CURRENT DRUGS AND THOSE IN ADVANCED DEVELOPMENT.CURRENT DRUG TARGETS. VOL. 5. ISSUE 7. P. 637 -646 73 79% 20
7 SCHEEN, AJ , (2010) CARDIOVASCULAR RISK-BENEFIT PROFILE OF SIBUTRAMINE.AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS. VOL. 10. ISSUE 5. P. 321-334 62 73% 32
8 HENNESS, S , PERRY, CM , (2006) ORLISTAT: A REVIEW OF ITS USE IN THE MANAGEMENT OF OBESITY.DRUGS. VOL. 66. ISSUE 12. P. 1625-1656 66 73% 37
9 ARA, R , BLAKE, L , GRAY, L , HERNANDEZ, M , CROWTHER, M , DUNKLEY, A , WARREN, F , JACKSON, R , REES, A , STEVENSON, M , ET AL (2012) WHAT IS THE CLINICAL EFFECTIVENESS AND COST-EFFECTIVENESS OF USING DRUGS IN TREATING OBESE PATIENTS IN PRIMARY CARE? A SYSTEMATIC REVIEW.HEALTH TECHNOLOGY ASSESSMENT. VOL. 16. ISSUE 5. P. 1-+ 86 46% 18
10 SIEBENHOFER, A , JEITLER, K , HORVATH, K , BERGHOLD, A , SIERING, U , SEMLITSCH, T , (2013) LONG-TERM EFFECTS OF WEIGHT-REDUCING DRUGS IN HYPERTENSIVE PATIENTS.COCHRANE DATABASE OF SYSTEMATIC REVIEWS. VOL. . ISSUE 3. P. - 53 74% 5

Classes with closest relation at Level 1


Rank Class id link
1 2331 WEIGHT LOSS MAINTENANCE//WEIGHT MAINTENANCE//WEIGHT LOSS
2 6263 DEXFENFLURAMINE//D FENFLURAMINE//FENFLURAMINE
3 17021 CARCINOID HEART DISEASE//VALVULOPATHY//BENFLUOREX
4 8413 RIMONABANT//ENDOCANNABINOIDS//TARANABANT
5 17145 SILDENAFIL ANALOGUE//ADV ANAL TEAM//ADULTERANTS
6 21448 PHENYLPROPANOLAMINE//NOREPHEDRINE//CUMULATIVE FOOD INTAKE
7 14744 TOPIRAMATE//TOPIRAMATE TOPAMAX//QUDEXY XR
8 19025 INTRAGASTRIC BALLOON//GASTRIC BALLOON//PREOPERATIVE WEIGHT LOSS
9 26657 OBESE YEARS//DURATION OF OBESITY//ILLUSTRATIVE MENU
10 15324 ECONOMICS & HUMAN BIOLOGY//SOCIAL MED OCCUPAT MED PUBL HLTH//OBESITY

Go to start page